Lapatinib prevents and ameliorates dermal fibrosis in bleomycin induced experimental scleroderma model
Journal of Medical Topics and Updates · 2024
DOI: 10.58651/jomtu.1404234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Topics and Updates, 2024. Verfasst von Berçem Afşar Karatepe und 6 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Scleroderma is a connective tissue disease characterized by endothelial damage and diffuse interstitial fibrosis. Lapatinib, a tyrosine kinase inhibitor, is a 4-anilinoquinol derivative. It inhibits many important signalling pathways including MAPK and PI3K. As a result, it affects cell cycle progression, apoptosis, angiogenesis and cell adhesion. Materials and Methods: Mice with an average age of 6 weeks and a weight of 20-25 g were divided into 6 equal groups (n=10 in each group). Mice in the control group (group A and group D), which were not treated with bleomycin (BLM), received sc phosphate buffered saline (PBS) daily. BLM was dissolved in FTS and administered to mice in groups B and C for 3 weeks, and to mice in groups E and F at a dose of sc 100 L (100 g) daily for 6 weeks. Mice in groups A, B and C were sacrificed at the end of week 3; mice in groups D, E and F were sacrificed at the end of week 6 and tissue samples were collected for further analysis. The mRNA expressions of TGF-β1 and fibronectin-1 were determined by RT-PCR.
Results
Repeated subcutaneous administration of BLM caused dermal inflammatory cell infiltration, increased skin thickness and dermal fibrosis at early and late stages. TGF-β1 and fibronectin-1 mRNA expressions were also evidently increased. In both prophylactic and therapeutic applications of lapatinib, TGF-β1 and fibronectin-1mRNA expressions decreased markedly. In addition, histopathological dermal necro- inflammation and fibrosis were reduced.
Conclusions
Lapatinib may exert anti-fibrotic effects in BLM-induced dermal fibrosis model. Studies show that lapatinib is a potential therapeutic agent, but it needs to be confirmed with in vivo studies.
Zitieren
APA
Karatepe, B. A., Yolbaş, S., Yıldırım, A., Hoşgün, D., Özercan, İ. H., Önalan, E., & Koca, S. S. (2024). Lapatinib prevents and ameliorates dermal fibrosis in bleomycin induced experimental scleroderma model. Journal of Medical Topics and Updates. https://doi.org/10.58651/jomtu.1404234
Vancouver
Karatepe BA, Yolbaş S, Yıldırım A, Hoşgün D, Özercan İH, Önalan E, et al. Lapatinib prevents and ameliorates dermal fibrosis in bleomycin induced experimental scleroderma model. Journal of Medical Topics and Updates. 2024. doi:10.58651/jomtu.1404234
BibTeX
@article{Karatepe2024,
author = {Karatepe, Berçem Afşar and Yolbaş, Servet and Yıldırım, Ahmet and Hoşgün, Derya and Özercan, İbrahim Hanifi and Önalan, Ebru and Koca, Süleyman Serdar},
title = {Lapatinib prevents and ameliorates dermal fibrosis in bleomycin induced experimental scleroderma model},
journal = {Journal of Medical Topics and Updates},
year = {2024},
doi = {10.58651/jomtu.1404234}
}
EUVIMED